水飞蓟素联合复方蛋氨酸胆碱治疗酒精性肝炎患者疗效及其对血清肝纤维化指标的影响*

doi:10.3969/j.issn.1672-5069.2024.03.008

Abstract

Abstract: Objective The aim of this study was to observe the clinical efficacy of silymarin and compound methionine choline combination in treating patients with alcoholic hepatitis (AH). Methods 101 patients with AH were admitted to our hospital between January 2021 and January 2023, and were randomly divided into control (n=50) and observation (n=51) groups, receiving oral compound methionine choline or oral compound methionine choline and silymarin combination treatment for six months. The liver function tests were detected by fully automatic biochemical analyser, serum laminin (LN), hyaluronic acid (HA), type Ⅲ procollagen N-terminal peptide (PCⅢ) and type Ⅳ collage (Ⅳ-C) levels were assayed by radioimmunoassay and serum peroxisome proliferators-activated receptor γ (PPARγ), leptin (LEP), adiponectin (APN) and interleukin 18 (IL-18) were determined by ELISA. Results At the end of six-month treatment, serum alanine transferase and aspartate transaminase levels in the observation group were(41.8±4.9)IU/L and (42.5±4.9)IU/L, both significantly lower than [(75.3±6.8)IU/L and (62.7±5.8)IU/L, respectively, P<0.05] in the control group; serum HA, PCⅢ and Ⅳ-C levels in the observation group were (103.6±13.5)μg/L, (94.2±9.8)μg/L and (75.2±8.6)μg/L, all significantly lower than [(146.2±15.3)μg/L, (125.8±13.3)μg/L and (112.3±14.5)μg/L, P<0.05] in the control; serum PPARγ, LEP and IL-18 levels in the observation group were (231.7±26.8)pg/mL, (5.4±0.7)μg/L and (92.5±11.7)ng/mL, all significantly lower than [(285.3±29.4)pg/mL, (8.3±0.9)μg/L and (118.5±12.4)ng/mL, respectively, P<0.05], while serum APN level was (15.4±1.7)ng/L, significantly higher than [(11.3±1.9)ng/L, P<0.05] in the control group. Conclusion The oral administration of compound methionine choline and silymarin combination in treatment of patients with AH is short-termly efficacious, which could improve liver function tests back to normal, and relieve liver fibrosis and body inflammatory reactions.

Key words: Alcoholic hepatitis, Silymarin, Compound methionine choline, Liver fibrosis, Therapy

Cheng Yanjie, Wang Pengfei, Li Jun. Clinical efficacy of silymarin and compound methionine choline combination in the treatment of patients with alcoholic hepatitis[J]. Journal of Practical Hepatology, 2024, 27(3): 349-352.

References

[1] Dong Y, Cui H, Sun L, et al. Assessment of left ventricular function in type 2 diabetes mellitus patients with non-alcoholic fatty liver disease using three-dimensional speckle-tracking echocardiography. Anatol J Cardiol,2020,23(1):41-48.
[2] 温青萍, 钱花, 巴桑, 等.探讨西藏地区恩替卡韦治疗对非AH合并慢性乙型肝炎患者肝纤维化程度的影响.中华肝脏病杂志,2022,30(3):304-308.
[3] 张夏霞, 李沙, 许陕陕, 等.1,25-二羟基维生素D3在蛋氨酸胆碱缺乏饮食诱导的大鼠肝脏脂质代谢中的作用.中华肝脏病杂志,2021,29(2):163-168.
[4] Gillessen A, Schmidt HH. Silymarin as supportive treatment in liver diseases: a narrative review. Adv Ther,2020,37(4):1279-1301.
[5] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪肝专家委员会.酒精性肝病防治指南(2018年更新版).实用肝脏病杂志,2018,21(2): 170-176.
[6] Wong T, Dang K, Ladhani S, et al. Prevalence of alcoholic fatty liver disease among adults in the United States, 2001-2016. JAMA,2019,321(17):1723-1725.
[7] Jiang ZB, Gao J, Chai YH, et al. Astragaloside alleviates alcoholic fatty liver disease by suppressing oxidative stress. Kaohsiung J Med Sci,2021,37(8):718-729.
[8] 李颖, 曹文富, 李金蝶.参麦兰苓汤对2型糖尿病合并非AH肝脏脂肪含量及肝纤维化的影响.中华中医药学刊,2022,40(6):144-148.
[9] 刘进国, 王暴魁.复方鳖甲软肝片联合丁二磺酸腺苷蛋氨酸和熊去氧胆酸治疗PBC患者疗效及其对血清肝纤维化指标的影响.实用肝脏病杂志,2018,21(3):340-343.
[10] Soleimani V, Delghandi PS, Moallem SA, et al. Safety and toxicity of silymarin, the major constituent of milk thistle extract:an updated review.Phytother Res, 2019, 33(6):1627-1638.
[11] Aljobaily N, Krutsinger K, Viereckl MJ, et al. Low-dose administration of cannabigerol attenuates inflammation and fibrosis associated with methionine/choline deficient diet-induced Nash model via modulation of cannabinoid receptor. Nutrients, 2022, 15(1):178-178.
[12] de Avelar CR, Nunes BVC, da Silva Sassaki B, et al. Efficacy of silymarin in patients with non-alcoholic fatty liver disease-thesiliver trial:a study protocol for a randomized controlled clinical trial. Trials, 2023, 24(1):177.
[13] 张修举, 郭瑞, 张引强, 等.益生菌联合水飞蓟宾对老年非酒精性肝炎患者糖脂代谢指标、肝功能及炎症因子改善作用研究.临床军医杂志,2023,51(2):206-209.
[14] Yao Z, Liang G, Lv ZL, et al. Taurine reduces liver damage in non-alcoholic fatty liver disease model in rats by down-regulating IL-9 and tumor growth factor TGF-B. Bull Exp Biol Med,2021,171(5):638-643.
[15] Bechynska K, Kosek V, Fenclova M, et al. The effect of mycotoxins and silymarin on liver lipidome of mice with non-alcoholic fatty liver disease. Biomolecules,2021,11(11):1723.
[16] Yang XD, Chen Z, Ye L, et al. Esculin protects against methionine choline-deficient diet-induced non-alcoholic steatohepatitis by regulating the Sirt1/NF-κB p65 pathway. Pharm Biol,2021,59(1):922-932.
[17] Madsen BS, Thiele M, Detlefsen S, et al. Prediction of liver fibrosis severity in alcoholic liver disease by human microfibrillar-associated protein 4. Liver Int,2020,40(7):1701-1712.
[18] Matthews DR, Li H, Zhou J, et al. Methionine-and choline-deficient diet-induced nonalcoholic steatohepatitis is associated with increased intestinal inflammation. Am J Pathol,2021,191(10):1743-1753.
[19] Aghemo A, Alekseeva OP, Angelico F, et al. Role of silymarin as antioxidant in clinical management of chronic liver diseases: a narrative review. Ann Med,2022,54(1):1548-1560.
[20] 南然, 李宜璇.清肝化湿活血汤联合水飞蓟宾胶囊对酒精性肝病患者肝纤维化指标的影响.实用医学杂志,2022,38(8):1022-1026.
[21] 周纪妹, 李臻.三七脂肝丸联合复方蛋氨酸胆碱治疗AH的临床研究.现代药物与临床,2021,36(4):727-730.
[22] Gong M, Lu H, Li L, et al.Integration of transcriptomics and metabonomics revealed the protective effects of hemp seed oil against methionine-choline-deficient diet-induced non-alcoholic steatohepatitis in mice. Food Funct,2023,14(4):2096-2111.
[23] Stephen Robert JM, Peddha MS, Srivastava AK. Effect of silymarin and quercetin in a miniaturized scaffold in Wistar rats against non-alcoholic fatty liver disease. ACS Omega,2021,6(32):20735-20745.

Clinical efficacy of silymarin and compound methionine choline combination in the treatment of patients with alcoholic hepatitis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Chen Congxin, Chen Xi, Wang Liping, et al. How to administrate steroids to patients with cholestasis and liver failure？ [J]. Journal of Practical Hepatology, 2024, 27(3): 321-323.
[2]	Zhao Yuwen, Zhu Chuanlong. Management of malnutrition and sarcopenia in patients with liver cirrhosis [J]. Journal of Practical Hepatology, 2024, 27(3): 324-328.
[3]	Yu Shanshan, Zhang Yeting, Wang Yuanpeng, et al. Changes of serum MMP-1, MMP-2, TIMP-1 and HIF-1α levels in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2024, 27(3): 329-332.
[4]	Luo Liangde, Ren Chengguo, Wang Shoujun, et al. Combination of entecavir and polyene phosphatidylcholine therapy in the treatment of patients with chronic hepatitit B and NASH [J]. Journal of Practical Hepatology, 2024, 27(3): 333-336.
[5]	Zhou Anqi, Meng Shuting, Wu Yingdong, et al. Low level viremia in patients with chronic hepatitis B receiving nucleos(t)ide analogue treatment [J]. Journal of Practical Hepatology, 2024, 27(3): 337-340.
[6]	Peng Yujing, Guo Hang, Chen Junguang. Liver fibrosis assessment by US elastography in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2024, 27(3): 345-348.
[7]	Xu Qiuping, Huang Bin, Chen Min, et al. Changes of peripheral blood MDSCs, serum CD38 level and hepatic interleukin-35 expression in patients with autoimmune hepatitis receiving prednisone and azathioprine combination therapy [J]. Journal of Practical Hepatology, 2024, 27(3): 374-377.
[8]	Jiang Zhengwei, Zhou Bingqing, Tang Jie, et al. Clinical feature of primary biliary cholangitis patients with serum anti glycoprotein 210 antibody positive [J]. Journal of Practical Hepatology, 2024, 27(3): 378-381.
[9]	Li Julan, Zhang Huatang, Zheng Yijuan, et al. Chinese herbal medicine compound,Fuzheng Huayu table, ameliorate liver fibrosis in patients with hepatitis B-induced liver cirrhosis receiving entecavir antiviral treatment [J]. Journal of Practical Hepatology, 2024, 27(3): 402-405.
[10]	Cai Junling, Su Li, Hao Li, et al. Efficacy of antiviral therapy based on sorfosbuvir combination in the treatment of patients with hepatitis C-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2024, 27(3): 406-409.
[11]	Yan Zhen, Zhao Bowen, Lin Guoying, et al. Clinical application of imaging three-dimensional visualization technique in guidance of hepatectomy in patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2024, 27(3): 438-441.
[12]	Li Weijian, Liu Xin, Shu Hongyan. Comparison of lauromacrogol and anhydrous ethanol sclerotherapy under ultrasound guidance in the treatment of patients with hepatic cysts [J]. Journal of Practical Hepatology, 2024, 27(3): 450-453.
[13]	Wang Lingru, Su Hong, Hao Xiaowei, et al. Disappearance of simple hepatic cysts after percutaneous transhepatic gallbladder drainage and lauromacrogol sclerotherapy under ultrasound guidance: A single center observation [J]. Journal of Practical Hepatology, 2024, 27(3): 454-457.
[14]	Sun Chao, Duan Xiaoyan, Ge Wensong, et al. Undifferentiated connective tissue disease associated liver fibrosis: A case report [J]. Journal of Practical Hepatology, 2024, 27(3): 470-472.
[15]	Ma Ruidong, Luo Shiqiao. Hepatic arterial infusion pump chemotherapy in treatment of patients with colorectal liver metastases [J]. Journal of Practical Hepatology, 2024, 27(3): 473-476.